- Raw materials
- Anti-infective Agents
- Cefamandole nafate
Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Cefamandole nafate API Manufacturers & Suppliers
1 verified results
All Cefamandole nafate data. Full access. Full negotiation power
Commercial-scale Suppliers
Employees: 150
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Cefamandole nafate | CAS No: 57268-80-1 | GMP-certified suppliers
A medication that treats various bacterial infections including respiratory, urinary tract, skin, and bone infections by targeting susceptible gram-positive and gram-negative bacteria.
Therapeutic categories
Product Snapshot
- Cefamandole nafate is available as an injectable small molecule antibiotic in powder form for solution
- It is primarily used for treating bacterial infections through intramuscular or intravenous administration
- This API is approved for use in the Canadian pharmaceutical market
Clinical Overview
The pharmacological activity of cefamandole nafate relies on its mechanism as a beta-lactam antibiotic, wherein it inhibits bacterial cell wall synthesis. This is achieved through binding to penicillin-binding proteins (PBPs), enzymes essential for the cross-linking of peptidoglycan layers in bacterial cell walls. Inhibition of these PBPs leads to loss of cell wall integrity and bacterial cell lysis, exerting bactericidal effects.
While specific clinical indications for cefamandole nafate may vary regionally, cephalosporins of this generation are generally used to treat infections such as respiratory tract infections, urinary tract infections, skin and soft tissue infections, and bone infections caused by susceptible organisms.
Key absorption, distribution, metabolism, and excretion (ADME) parameters for cefamandole nafate include its hydrolysis to active cefamandole following administration. Metabolism primarily occurs via hydrolysis, with renal excretion of unchanged drug and metabolites constituting the main elimination pathway. The pharmacokinetic profile supports dosing adjustments in patients with renal impairment.
Safety and toxicity considerations include potential hypersensitivity reactions common to beta-lactams, such as allergic responses ranging from rash to anaphylaxis. Cephalosporins may also cause alterations in coagulation parameters and gastrointestinal disturbances. Careful assessment in patients with penicillin allergy is advised. Nephrotoxicity and hematologic effects are rare but reported.
Notable brand names and formulations may differ globally, underscoring the need for verification of equivalence and regulatory status in specific markets.
From an API sourcing perspective, cefamandole nafate requires stringent quality control to ensure purity, stability, and compliance with pharmacopeial standards. Manufacturing processes must account for the sensitive beta-lactam ring to prevent degradation. Suppliers should provide comprehensive documentation regarding batch consistency, impurity profiles, and regulatory certifications to align with global pharmaceutical quality requirements.
Identification & chemistry
| Generic name | Cefamandole nafate |
|---|---|
| Molecule type | Small molecule |
| CAS | 57268-80-1 |
| DrugBank ID | DB14725 |
Formulation & handling
- Cefamandole nafate is intended for parenteral administration, primarily intravenous and intramuscular routes.
- As a small molecule antibiotic, it requires reconstitution from powder to solution prior to injection.
- Due to limited water solubility, dissolution conditions and storage of the reconstituted solution should be carefully controlled to maintain stability.
Regulatory status
| Lifecycle | The API’s patent protection has expired in Canada, allowing for generic competition and wider market availability. The product is now in a mature phase within this market. |
|---|
| Markets | Canada |
|---|
Supply Chain
| Supply chain summary | Cefamandole nafate is supplied in the Canadian market through branded injectable formulations available in multiple dosages. The presence of branded products in Canada indicates established originator companies, though limited geographic spread suggests a regional focus. Patent expiry status is not specified, but the availability of multiple dosage forms may imply potential for existing or upcoming generic competition. |
|---|
Cefamandole nafate is a type of Anti-infective Agents
Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.
Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.
The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.
The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.
In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.
Cefamandole nafate API manufacturers & distributors
Compare qualified Cefamandole nafate API suppliers worldwide. We currently have 1 companies offering Cefamandole nafate API, with manufacturing taking place in 1 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Chr. Olesen Group | Distributor | Denmark | China | CoA, USDMF | 252 products |
When sending a request, specify which Cefamandole nafate API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Cefamandole nafate API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
